Alps Advisors Inc Pds Biotechnology Corp Transaction History

Alps Advisors Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$4.8 - $6.4 $787 - $1,049	164 Added 0.72%	22,822 $115,000
Q2 2023 Aug 14, 2023	BUY	$5.03 - $9.9 $19,516 - $38,412	3,880 Added 20.66%	22,658 $113,000
Q1 2023 May 10, 2023	SELL	$5.68 - $11.99 $3,345 - $7,062	-589 Reduced 3.04%	18,778 $115,000
Q4 2022 Feb 14, 2023	BUY	$3.28 - $13.2 $63,523 - $255,644	19,367 New	19,367 $255,000
Q2 2022 Aug 11, 2022	SELL	$3.05 - $6.68 $89,124 - $195,196	-29,221 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$4.78 - $8.43 $17,614 - $31,064	-3,685 Reduced 11.2%	29,221 $181,000
Q4 2021 Feb 09, 2022	BUY	$7.76 - $14.35 $255,350 - $472,201	32,906 New	32,906 $267,000

4.05M

253K

70.4K

Ticker PDSB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,458,700
Market Cap $43M
Description
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.